Alkermes plc
ALKS
Rank in Stocks
#2726
Alkermes plc, a biopharmaceutical company, engages in the research,... Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Share Price
$41.39
Last synced: 2026-10-16
Market Cap
$6.94B
Change (1 day)
3.22%
Change (1 year)
36.78%
Country
IE
Trade Alkermes plc (ALKS)
Category
Healthcare
Earnings for Alkermes plc (ALKS)
Earnings in Jun 2026 TTM: $97.32M
According to Alkermes plc latest financial reports the company's current earnings are $97.32M. In 2023 the company made an earning of $421.52M, an increase over its 2022 earnings that were of $-31.13M. The earnings displayed on this page are the earnings before interest and taxes or simply EBIT.
Earnings history for Alkermes plc from 2000 to 2026
Earnings at the end of each year
| Year | Earnings | Change |
|---|---|---|
| 2026 (TTM) | $97.32M | -78.07% |
| 2024 | $443.75M | 5.27% |
| 2023 | $421.52M | -1,454.15% |
| 2022 | $-31.13M | -135.48% |
| 2021 | $87.73M | -190.87% |
| 2020 | $-96.54M | -51.01% |
| 2019 | $-197.06M | 55.20% |
| 2018 | $-126.97M | -11.38% |
| 2017 | $-143.27M | -33.17% |
| 2016 | $-214.39M | -4.29% |
| 2015 | $-224.01M | 1,496.73% |
| 2014 | $-14.03M | -139.58% |
| 2013 | $35.44M | 0.00% |
| 2012 | $35.44M | -130.98% |
| 2011 | $-114.39M | 146.05% |
| 2010 | $-46.49M | 4.00% |
| 2009 | $-44.70M | -134.12% |
| 2008 | $131.01M | -24.20% |
| 2007 | $172.83M | 1,539.29% |
| 2006 | $10.54M | 0.00% |
| 2005 | 0.00 | -100.00% |
| 2004 | $-75.17M | 0.00% |
| 2003 | 0.00 | -100.00% |
| 2002 | $-106.90M | 74.23% |
| 2001 | $-61.35M | 263.71% |
| 2000 | $-16.87M | 0.00% |
Earnings for similar companies or competitors
| Company | Earnings | Earnings Difference | Country |
|---|---|---|---|
| $5.27B | 5,320.16% |
US
|
|
| $-3.09B | -3,272.01% |
US
|
|
| $-4.02B | -4,226.79% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | 1,904.37% |
NL
|
